File Name: probiotics and mental health .zip
Probiotics are living bacteria, which when ingested in adequate amounts, confer health benefits. Gut microbes are suggested to play a role in many psychiatric disorders and could be a potential therapeutic target. Between the gut and the brain, there is a bi-directional communication pathway called the microbiota-gut-brain axis. The purpose of this review is to examine data from recent interventional studies focusing on probiotics and the gut-brain axis for the treatment of depression, anxiety and schizophrenia. Probiotics are likely to improve depression but not schizophrenia. Regarding anxiety, there is only one trial which showed an effect of a multispecies probiotic. However, determinants like the duration of treatment, dosage and interactions have not been thoroughly investigated and deserve more scientific attention.
For centuries, individuals have consumed probiotics as a means of improving quality of life and preventing disease. The gut microbiota refers to the collection of microorganisms residing within the gut. Psychiatric disorders show profound alterations of gut microbiota composition along with a lack of bacterial diversity. Specific subtypes of probiotics and prebiotics fibers that promote the growth of beneficial bacteria are referred to as psychobiotics , which impact the gut-brain axis and result in modifications of mood, anxiety, and cognitive function. It is essential for psychiatrists to improve their understanding of psychobiotic mechanisms and the evidence that supports their use in practice.
Lifestyle Psychiatry View all 19 Articles. Recent demonstration that probiotics administration has positive effects on mood state in healthy populations suggests its possible role as an adjunctive therapy for depression in clinical populations and as a non-invasive strategy to prevent depressive mood state in healthy individuals. The present study extends current knowledge on the beneficial effects of probiotics on psychological well-being, as measured by changes in mood e. For this double-blind, placebo-controlled study 38 healthy volunteers assigned to an experimental or control group assumed a daily dose of a probiotic mixture containing Lactobacillus fermentum LF16, L. Mood, personality dimensions, and sleep quality were assessed four times before the beginning of the study, at 3 and 6 weeks, and at 3 weeks of washout.
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Patients suffering from depression experience significant mood, anxiety, and cognitive symptoms. Currently, most antidepressants work by altering neurotransmitter activity in the brain to improve these symptoms. The aim of this review is to analyze the current body of research assessing the effects of probiotics, on symptoms of depression in humans. A systematic search of five databases was performed and study selection was completed using the preferred reporting items for systematic reviews and meta-analyses process.
Rapid scientific and technological advances have allowed for a more detailed understanding of the relevance of intestinal microbiota, and the entire body-wide microbiome, to human health and well-being. Rodent studies have provided suggestive evidence that probiotics e. However, despite the advances in the area of gastro-biological psychiatry, it becomes clear that there remains an urgent need to explore the value of beneficial microbes in controlled clinical investigations. With the history explored in this series, it is fair to ask if we are now on the cusp of major clinical breakthroughs, or are we merely in the quicksand of Autointoxication II? Though the first two parts of this series, we have attempted to provide a historical and contextual approach to the more direct lines of contemporary evidence as it relates to gut microbiota, its intentional manipulation, and mental health.
Metrics details. Current treatment of major depressive disorder MDD often does not achieve full remission of symptoms. Evidence has confirmed the modulation of the gut—brain—microbiota axis as a promising approach in MDD patients.